Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

doi:10.19401/j.cnki.1007-3639.2017.02.012

Abstract

Abstract: The WNT/β-catenin signaling pathway plays a critical role in cellular proliferation, differentiation and organogenesis. Aberration activation of WNT/β-catenin pathway and dysregulation of miRNA related with this pathway are involved in oncogenesis and tumor progression in primary lung cancer. Understanding the mechanism of the WNT/β-catenin signaling pathway and illuminating the interaction between miRNA and the members of this pathway may improve the perspectives of using these molecules as potential therapeutic targets for primary lung cancer. This review focused on the participation of the WNT/β-catenin signaling pathway and miRNA in lung cancer and discussion of potential targets for this malignancy therapy in the future.

Key words: Lung cancer, WNT/β-catenin signaling pathway, miRNA

LU Zhouyi, CHEN Xiaofeng. Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer[J]. China Oncology, 2017, 27(2): 151-155.

[1]	LI Ya, LIU Hui, REN Jingjing, LI Xiaofu, ZHI Yanfang. Early diagnostic value of methylation in promoter region of FAM19A4, PAX1 and miRNA124-2 in cervical lesions [J]. China Oncology, 2024, 34(8): 734-744.
[2]	WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen. A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis [J]. China Oncology, 2024, 34(7): 628-638.
[3]	QIAN Bin, CHEN Haiquan. Important progress in surgical treatment of lung cancer in 2023 [J]. China Oncology, 2024, 34(4): 335-339.
[4]	LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications [J]. China Oncology, 2024, 34(4): 368-379.
[5]	JIANG Mengqi, HAN Yuchen, FU Xiaolong. Research progress on H-E stained whole slide image analysis by artificial intelligence in lung cancer [J]. China Oncology, 2024, 34(3): 306-315.
[6]	WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856.
[7]	ZHANG Lingling, WANG Xiangyi, WEI Xing, LIN Li, TANG Chuanhao, LIANG Jun. A study on prevention and treatment of chemotherapy induced nausea and vomiting in non-small cell lung cancer patients with low-frequency electrical stimulator for antiemesis [J]. China Oncology, 2023, 33(8): 776-781.
[8]	ZHANG Haoting, ZHENG Jing, FU Mengjiao, ZHOU Jianying. Research progress on thyroid dysfunction induced by immunotherapy for lung cancer [J]. China Oncology, 2023, 33(7): 701-706.
[9]	WU Jing, ZHOU Juan, SU Chunxia. Advances in fatty acid metabolism reprogramming of lung cancer [J]. China Oncology, 2023, 33(5): 517-526.
[10]	SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022 [J]. China Oncology, 2023, 33(3): 218-227.
[11]	ZOU Chunyuan, XU Xiaofeng, LU Renquan, GUO Lin. Detection of p53, PGP9.5, SOX2, GAGE7, GBU4-5 and MAGE A1 protein levels in lung cancer tissues and peripheral blood and their clinical value [J]. China Oncology, 2023, 33(1): 36-44.
[12]	HE Liyuan, WANG Yudong. Research progress of ALK kinase domain drug resistance mutation and its future countermeasures [J]. China Oncology, 2022, 32(8): 736-746.
[13]	HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634.
[14]	WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi. Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer [J]. China Oncology, 2022, 32(6): 469-477.
[15]	SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486.

Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments